
Callergin, an investigational nasal spray with barrier-forming iota-carrageenan, demonstrates potential in managing grass pollen-induced allergic rhinitis (AR). In a randomized trial involving 42 participants, although the mean Total Nasal Symptom Score (TNSS) change did not significantly differ between Callergin and no treatment, a post-hoc analysis revealed a significant reduction in TNSS at 3 hours post-treatment. Rhinorrhea and congestion were the most impacted symptoms. Callergin proved safe and well-tolerated, suggesting its efficacy in alleviating nasal allergy symptoms. This nonpharmacological approach offers promise for AR management.
Like
Save
Share